Health
Post-Transcriptional Genetic Silencing of BCL11A to Treat Sickle Cell Disease – nejm.org
Original Article from The New England Journal of Medicine — Post-Transcriptional Genetic Silencing of BCL11A to Treat Sickle Cell Disease
From the DanaFarber/Boston Childrens Cancer and Blood Disorders Center, Harvard Medical School (E.B.E., L.E.L., A.B., C.B., M.F.C., B.M., K.B., S.-Y.P., W.B.L., C.D., M.M.H., D.A.W.), the Harvard Stem Cell Institute, Harvard Medical School (A.B., C.B.), the Gene Therapy Program, DanaFarber/Boston Childrens Cancer and Blood Disorders Center (A.B., M.F.C., B.M., E.M., A.F., S.-Y.P., C.D., D.A.W.), the Division of Hematology, Brigham and Womens Hospital, Harvard Medical School (M. Achebe), the Connell…
-
Noosa News23 hours agoWhere, when and why? Everything you need to know about Sunday’s pro-Palestine protest march in Brisbane
-
General19 hours agoIndia to defend ‘red lines’ as fresh tariffs loom
-
General16 hours agoAlbanese government to freeze construction code until 2029, fast-track housing approvals
-
Noosa News18 hours agoColombian Director Simón Mesa Soto’s ‘A Poet’ Is 2025’s Winner of Melbourne International Film Festival’s Bright Horizons Award